Advances in pulmonary therapy

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

7 Citations (Scopus)

Abstract

Pharmacologically active substances have been administered to humans for thousands of years. However, it is only in relatively recent times that the true nature of drug delivery to the human body has become an exact science. Today, drugs are delivered via many portals into the body using a variety of dosage forms which allow medicament administration, for example, orally or parenterally. One relatively recent pharmaceutical development is delivery via the lung. Although the breathing of “vapors” has been used since ancient times as a way of relieving respiratory problems, the effective acceptance and mass commercialization of inhaled respiratory medicines was not achieved until 1948 when Abbot Laboratories developed the Aerohaler for inhaled penicillin-G powder and then revolutionized the field in 1955 with the advent of the pressurized metered dose inhaler (pMDI) (1,2). Since this inception, the range of inhaler products and medicaments has grown and expanded to encompass alternative drug delivery systems, namely those based on the dry powder inhaler (DPI), and combination products.
Original languageEnglish
Title of host publicationAdvanced drug formulation design to optimize therapeutic outcomes
EditorsRobert O. Williams, David R. Taft, Jason T. McConville
PublisherCRC Press (Taylor and Francis)
Chapter1
Pages1-52
Number of pages52
ISBN (Electronic)9780429143519, 9781420043884
DOIs
Publication statusPublished - 2008
Externally publishedYes

Publication series

NameDrugs and the pharmaceutical sciences
PublisherCRC Press
Volume172

Fingerprint

Dive into the research topics of 'Advances in pulmonary therapy'. Together they form a unique fingerprint.

Cite this